IP Library Granted Patent US 7,317,949
Granted Patent B2
US 7,317,949 · App. 10/828,027 · Granted Jan 8, 2008

Energy induced bulking and buttressing of tissues for incontinence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,317,949
App. No.
10/828,027
Granted
Jan 8, 2008
Kind
B2
Abstract

Methods, devices, and systems for treating the support structures of the body, particularly for incontinence, take advantage of two mechanisms to enhance the support provided by the fascia, ligaments and tendons: first, the invention increases a modulus of elasticity of these tissues, and particularly of the fascial tissues. The increase in modulus can be effected by directing sufficient energy to the fascial tissue so as to promote the formation of scar tissue. The second mechanism attaches tissue planes together, often by directing energy to an interface between adjacent fascial tissues.

Claims (64)

1. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from an energy-directing element of a probe to a collagenous target tissue comprising or supporting a urethra of a patient, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue inhibiting the incontinence;

limiting the energy so as to avoid shrinkage of the collagenous target tissue; and

controlling the energy in an open loop manner using dosimetry.

2. The method of claim 1 , wherein the energy comprises RF energy delivered with an electrode of the probe.

3. The method of claim 2 , further comprising advancing the electrode of the probe into tissue, the electrode comprising a needle electrode.

4. The method of claim 1 , further comprising introducing the probe transvaginally.

5. A method for inhibiting incontinence of a patient, the method comprising:

introducing a probe transvaginally;

transmitting energy from the probe to a target tissue of a patient, the energy being transmitted so as to induce a healing response in the target tissue, the healing response inhibiting the incontinence; and

limiting the energy so as to avoid shrinkage of the target tissue.

6. The method of claim 5 , further comprising controlling the energy in an open loop manner using dosimetry.

7. The method of claim 5 , further comprising controlling the energy using a time-limited circuit so as to inhibit overtreatment.

8. The method of claim 5 , wherein the target tissue comprises a urethra or supports the urethra.

9. The method of claim 5 , wherein the target tissue comprises a bladder neck.

10. The method of claim 5 , wherein the healing response increases a modulus of elasticity of the target tissue.

11. The method of claim 5 , wherein the healing response affixes adjacent tissue planes together.

12. The method of claim 5 , wherein the target tissue comprises a collagenous tissue, and wherein the healing response comprises bulking or buttressing of the collagenous tissue.

13. The method of claim 5 , wherein the target tissue is heated to a temperature of 45° C. or greater.

14. A system for treatment of incontinence of a patient, the system comprising:

a probe having an energy directing element comprising a needle electrode, the probe insertable into a body of the patient and configured for coupling the energy directing element with a target tissue of or near a bladder neck or urethra of the patient by advancing the electrode into the target tissue;

a control circuit coupled to the probe, the control circuit configured to energize the energy directing element so as to transmit sufficient energy from the energy directing element to the target tissue to induce a target tissue altering healing response, the control circuit programmed to limit the energy to maintain temperature of the target tissue within a target temperature range so that the target tissue, as altered by the healing response, inhibits incontinence without shrinking of the target tissue.

15. The system of claim 14 , wherein the control circuit is configured to limit the energy in an open-loop manner using dosimetry.

16. The system of claim 15 , wherein the control circuit comprises a timing circuit configured to limit an energy application time.

17. The system of claim 16 , wherein the energy application time of the control circuit is suitable for treatment of the target tissue with the probe at a single treatment location.

18. The system of claim 14 , wherein the control circuit is configured to limit the energy so as to inhibit collagenous tissue contraction of the target tissue.

19. A method for inhibiting incontinence of a patient, the method comprising:

transmitting RE energy from a needle electrode of a probe to a collagenous target tissue comprising or supporting a urethra of a patient by advancing the electrode into tissue, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue and the bulking or buttressing of the collagenous target tissue inhibiting the incontinence; and

limiting the energy so as to avoid shrinkage of the collagenous target tissue.

20. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from an energy-directing element of a probe introduced transvaginally to a collagenous target tissue comprising or supporting a urethra of a patient, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue and the bulking or buttressing of the collagenous target tissue inhibiting the incontinence; and

limiting the energy so as to avoid shrinkage of the collagenous target tissue.

21. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from a probe to a target tissue of a patient, the energy being transmitted so as to induce a healing response in the target tissue, the healing response inhibiting the incontinence; and

controlling the energy in an open loop manner using dosimetry.

22. A method for inhibiting incontinence of a patient, the method comprising:

introducing a probe transvaginally;

transmitting energy from the probe to a target tissue of a patient, the energy being transmitted so as to induce a healing response in the target tissue, the healing response inhibiting the incontinence; and

controlling the energy using a time-limited circuit so as to inhibit overtreatment.

23. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from a probe to a target tissue of a patient, the energy being transmitted so as to induce a healing response in the target tissue, the healing response inhibiting the incontinence, wherein the healing response affixes adjacent tissue planes together; and

controlling the energy in an open loop manner using dosimetry.

24. A method for inhibiting incontinence of a patient, the method comprising:

transmitting RF energy from a needle electrode of a probe to a collagenous target tissue comprising or supporting a urethra of a patient by advancing the electrode into tissue, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue inhibiting the incontinence; and

limiting the energy so as to avoid shrinkage of the collagenous target tissue.

25. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from an energy-directing element of a probe introduced transvaginally to a collagenous target tissue comprising or supporting a urethra of a patient, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue inhibiting the incontinence; and

limiting the energy so as to avoid shrinkage of the collagenous target tissue.

26. A method for inhibiting incontinence of a patient, the method comprising:

transmitting energy from a probe to a target tissue of a patient, the energy being transmitted so as to induce a healing response in the target tissue, the healing response inhibiting the incontinence;

limiting the energy so as to avoid shrinkage of the target tissue; and

controlling the energy in an open loop manner using dosimetry.

27. A system for treatment of incontinence of a patient, the system comprising:

a probe having an energy directing element, the probe insertable into a body of the patient and configured for coupling the energy directing element with a target tissue of or near a bladder neck or urethra of the patient;

a control circuit coupled to the probe, the control circuit configured to energize the energy directing element so as to transmit sufficient energy from the energy directing element to the target tissue to induce a target tissue altering healing response, the control circuit programmed to limit the energy in an open-loop manner using dosimetry to maintain temperature of the target tissue within a target temperature range so that the target tissue, as altered by the healing response, inhibits incontinence without shrinking of the target tissue.

28. A system for treatment of incontinence of a patient, the system comprising:

a probe having an energy directing element, the probe insertable into a body of the patient and configured for coupling the energy directing element with a target tissue of or near a bladder neck or urethra of the patient;

a control circuit coupled to the probe, the control circuit configured to energize the energy directing element so as to transmit sufficient energy from the energy directing element to the target tissue to induce a target tissue altering healing response, the control circuit programmed to limit the energy in an open-loop manner using dosimetry to maintain temperature of the target tissue within a target temperature range so that the target tissue, as altered by the healing response, inhibits incontinence without shrinking of the target tissue;

wherein the control circuit comprises a timing circuit configured to limit an energy application time.

29. A system for treatment of incontinence of a patient, the system comprising:

a probe having an energy directing element, the probe insertable into a body of the patient and configured for coupling the energy directing element with a target tissue of or near a bladder neck or urethra of the patient;

a control circuit coupled to the probe, the control circuit configured to energize the energy directing element so as to transmit sufficient energy from the energy directing element to the target tissue to induce a target tissue altering healing response, the control circuit programmed to limit the energy in an open-loop manner using dosimetry to maintain temperature of the target tissue within a target temperature range so that the target tissue, as altered by the healing response, inhibits incontinence without shrinking of the target tissue;

wherein the control circuit comprises a timing circuit configured to limit an energy application time; and

wherein the energy application time of the control circuit is suitable for treatment of the target tissue with the probe at a single treatment location.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0318. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Sep 6, 2016
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 039919/0017 →
CHANGE OF NAME Recorded Jan 11, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037473/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037473/0260 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0318 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →
RELEASE OF SECURITY INTEREST Recorded Apr 18, 2011
From: CIT HEALTHCARE LLC
To: SOLARANT MEDICAL, INC.
Reel/Frame 026142/0160 →
SECURITY AGREEMENT Recorded Aug 17, 2006
From: SOLARANT MEDICAL, INC.
To: CIT HEALTHCARE LLC
Reel/Frame 018120/0843 →